Diminazene Ameliorates Neuroinflammation by Suppression of Astrocytic miRNA-224-5p/NLRP3 Axis in Alzheimer’s Disease Model

References

• Raskin J, Cummings J, Hardy J, Schuh K, Dean RA. Neurobiology of Alzheimer’s disease: integrated molecular, physiological, anatomical, biomarker, and cognitive dimensions. Curr Alzheimer Res. 2015;12(8):712–722. doi:10.2174/1567205012666150701103107
   PubMed Web of Science ®Google Scholar
• Deardorff WJ, Grossberg GT. Targeting neuroinflammation in Alzheimer’s disease: evidence for NSAIDs and novel therapeutics. Expert Rev Neurother. 2017;17(1):17–32. doi:10.1080/14737175.2016.1200972
   PubMed Web of Science ®Google Scholar
• Cai M, Lee JH, Yang EJ. Electroacupuncture attenuates cognition impairment via anti-neuroinflammation in an Alzheimer’s disease animal model. J Neuroinflammation. 2019;16(1):264. doi:10.1186/s12974-019-1665-3
   PubMed Web of Science ®Google Scholar
• Royea J, Martinot P, Hamel E. Memory and cerebrovascular deficits recovered following angiotensin IV intervention in a mouse model of Alzheimer’s disease. Neurobiol Dis. 2020;134:104644. doi:10.1016/j.nbd.2019.104644
   PubMedGoogle Scholar
• Jackson L, Eldahshan W, Fagan SC, Ergul A. Within the brain: the renin angiotensin system. Int J Mol Sci. 2018;19(3):876. doi:10.3390/ijms19030876
   PubMed Web of Science ®Google Scholar
• Feng Y, Xia H, Santos RA, Speth R, Lazartigues E. Angiotensin-converting enzyme 2: a new target for neurogenic hypertension. Exp Physiol. 2010;95(5):601–606. doi:10.1113/expphysiol.2009.047407
   PubMedGoogle Scholar
• Jiang T, Gao L, Lu J, Zhang YD. ACE2-Ang-(1-7)-mas axis in brain: a potential target for prevention and treatment of ischemic stroke. Curr Neuropharmacol. 2013;11(2):209–217. doi:10.2174/1570159X11311020007
   PubMed Web of Science ®Google Scholar
• Vickers C, Hales P, Kaushik V, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem. 2002;277(17):14838–14843. doi:10.1074/jbc.M200581200
   PubMed Web of Science ®Google Scholar
• Kehoe PG, Wong S, Al Mulhim N, Palmer LE, Miners JS. Angiotensin-converting enzyme 2 is reduced in Alzheimer’s disease in association with increasing amyloid-β and tau pathology. Alzheimers Res Ther. 2016;8(1):50. doi:10.1186/s13195-016-0217-7
   PubMedGoogle Scholar
• Kamel AS, Abdelkader NF, Abd El-Rahman SS, Emara M, Zaki HF, Khattab MM. Stimulation of ACE2/ANG(1-7)/mas axis by diminazene ameliorates Alzheimer’s disease in the D-galactose-ovariectomized rat model: role of PI3K/Akt pathway. Mol Neurobiol. 2018;55(10):8188–8202. doi:10.1007/s12035-018-0966-3
   PubMed Web of Science ®Google Scholar
• Liddelow SA, Barres BA. Reactive astrocytes: production, function, and therapeutic potential. Immunity. 2017;46(6):957–967. doi:10.1016/j.immuni.2017.06.006
   PubMed Web of Science ®Google Scholar
• Evans CE, Miners JS, Piva G, et al. ACE2 activation protects against cognitive decline and reduces amyloid pathology in the Tg2576 mouse model of Alzheimer’s disease. Acta Neuropathol. 2020;139(3):485–502. doi:10.1007/s00401-019-02098-6
   PubMed Web of Science ®Google Scholar
• Bradburn S, Murgatroyd C, Ray N. Neuroinflammation in mild cognitive impairment and Alzheimer’s disease: a meta-analysis. Ageing Res Rev. 2019;50:1–8. doi:10.1016/j.arr.2019.01.002
   PubMed Web of Science ®Google Scholar
• Morales I, Jiménez JM, Mancilla M, Maccioni RB. Tau oligomers and fibrils induce activation of microglial cells. J Alzheimers Dis. 2013;37(4):849–856. doi:10.3233/JAD-131843
   PubMed Web of Science ®Google Scholar
• Takousis P, Sadlon A, Schulz J, et al. Differential expression of microRNAs in Alzheimer’s disease brain, blood, and cerebrospinal fluid. Alzheimers Dement. 2019;15(11):1468–1477. doi:10.1016/j.jalz.2019.06.4952
   PubMed Web of Science ®Google Scholar
• Wang M, Li Z, Zuo Q. miR-194-5p inhibits LPS-induced astrocytes activation by directly targeting neurexophilin 1. Mol Cell Biochem. 2020;471(1–2):203–213. doi:10.1007/s11010-020-03780-0
   PubMedGoogle Scholar
• Fang X, Wang H, Zhuo Z, et al. miR-141-3p inhibits the activation of astrocytes and the release of inflammatory cytokines in bacterial meningitis through down-regulating HMGB1. Brain Res. 2021;1770:147611. doi:10.1016/j.brainres.2021.147611
   PubMedGoogle Scholar
• Duan R, Xue X, Zhang QQ, et al. ACE2 activator diminazene aceturate ameliorates Alzheimer’s disease-like neuropathology and rescues cognitive impairment in SAMP8 mice. Aging. 2020;12(14):14819–14829. doi:10.18632/aging.103544
   PubMedGoogle Scholar
• Li S, Li Y, Xu H, et al. ACE2 attenuates epithelial-mesenchymal transition in MLE-12 cells induced by silica. Drug Des Devel Ther. 2020;14:1547–1559. doi:10.2147/DDDT.S252351
   PubMed Web of Science ®Google Scholar
• Yao Y, Huang JZ, Chen Y, Hu HJ, Tang X, Li X. Effects and mechanism of amyloid β1-42 on mitochondria in astrocytes. Mol Med Rep. 2018;17(5):6997–7004. doi:10.3892/mmr.2018.8761
   PubMedGoogle Scholar
• Sun X, Deng Y, Fu X, Wang S, Duan R, Zhang Y. AngIV-analog dihexa rescues cognitive impairment and recovers memory in the APP/PS1 mouse via the PI3K/AKT signaling pathway. Brain Sci. 2021;11(11):1487. doi:10.3390/brainsci11111487
   PubMedGoogle Scholar
• Duan R, Wang SY, Wei B, et al. Angiotensin-(1-7) analogue AVE0991 modulates astrocyte-mediated neuroinflammation via lncRNA SNHG14/miR-223-3p/NLRP3 pathway and offers neuroprotection in a transgenic mouse model of Alzheimer’s disease. J Inflamm Res. 2021;14:7007–7019. doi:10.2147/JIR.S343575
   PubMed Web of Science ®Google Scholar
• Yang CC, Lin CC, Hsiao LD, Kuo JM, Tseng HC, Yang CM. Lipopolysaccharide-induced matrix metalloproteinase-9 expression associated with cell migration in rat brain astrocytes. Int J Mol Sci. 2019;21(1):259. doi:10.3390/ijms21010259
   PubMed Web of Science ®Google Scholar
• Ebrahimi T, Rust M, Kaiser SN, et al. α1-antitrypsin mitigates NLRP3-inflammasome activation in amyloid β1-42-stimulated murine astrocytes. J Neuroinflammation. 2018;15(1):282. doi:10.1186/s12974-018-1319-x
   PubMedGoogle Scholar
• Putteeraj M, Fairuz YM, Teoh SL. MicroRNA dysregulation in Alzheimer’s disease. CNS Neurol Disord Drug Targets. 2017;16(9):1000–1009. doi:10.2174/1871527316666170807142311
   PubMedGoogle Scholar
• Molina-Van den Bosch M, Jacobs-Cachá C, Vergara A, Serón D, Soler MJ. El rol del sistema renina angiotensina a nivel cerebral [The renin-angiotensin system and the brain]. Hipertens Riesgo Vasc. 2021;38(3):125–132. Spanish. doi:10.1016/j.hipert.2020.12.001
   PubMedGoogle Scholar
• Holmes C. Review: systemic inflammation and Alzheimer’s disease. Neuropathol Appl Neurobiol. 2013;39(1):51–68. doi:10.1111/j.1365-2990.2012.01307.x
   PubMed Web of Science ®Google Scholar
• Perry VH, Holmes C. Microglial priming in neurodegenerative disease. Nat Rev Neurol. 2014;10(4):217–224. doi:10.1038/nrneurol.2014.38
   PubMed Web of Science ®Google Scholar
• Takeda S, Sato N, Morishita R. Systemic inflammation, blood-brain barrier vulnerability and cognitive/non-cognitive symptoms in Alzheimer disease: relevance to pathogenesis and therapy. Front Aging Neurosci. 2014;6:171. doi:10.3389/fnagi.2014.00171
   PubMed Web of Science ®Google Scholar
• Schroder K, Zhou R, Tschopp J. The NLRP3 inflammasome: a sensor for metabolic danger? Science. 2010;327(5963):296–300. doi:10.1126/science.1184003
   PubMed Web of Science ®Google Scholar
• Zhang Q, Tao X, Xia S, et al. Emodin attenuated severe acute pancreatitis via the P2X ligand-gated ion channel 7/NOD-like receptor protein 3 signaling pathway. Oncol Rep. 2019;41(1):270–278. doi:10.3892/or.2018.6844
   PubMed Web of Science ®Google Scholar
• Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014;15(8):509–524. doi:10.1038/nrm3838
   PubMed Web of Science ®Google Scholar
• Swarbrick S, Wragg N, Ghosh S, Stolzing A. Systematic review of miRNA as biomarkers in Alzheimer’s disease. Mol Neurobiol. 2019;56(9):6156–6167. doi:10.1007/s12035-019-1500-y
   PubMed Web of Science ®Google Scholar
• Nagaraj S, Zoltowska KM, Laskowska-Kaszub K, Wojda U. microRNA diagnostic panel for Alzheimer’s disease and epigenetic trade-off between neurodegeneration and cancer. Ageing Res Rev. 2019;49:125–143. doi:10.1016/j.arr.2018.10.008
   PubMed Web of Science ®Google Scholar
• Millan MJ. Linking deregulation of non-coding RNA to the core pathophysiology of Alzheimer’s disease: an integrative review. Prog Neurobiol. 2017;156:1–68. doi:10.1016/j.pneurobio.2017.03.004
   PubMedGoogle Scholar
• Wang WX, Rajeev BW, Stromberg AJ, et al. The expression of microRNA miR-107 decreases early in Alzheimer’s disease. and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J Neurosci. 2008;28(5):1213–1223. doi:10.1523/JNEUROSCI.5065-07.2008
   PubMed Web of Science ®Google Scholar
• Hébert SS, Horré K, Nicolaï L, et al. MicroRNA regulation of Alzheimer’s disease amyloid precursor protein expression. Neurobiol Dis. 2009;33(3):422–428. doi:10.1016/j.nbd.2008.11.009
   PubMed Web of Science ®Google Scholar
• Absalon S, Kochanek DM, Raghavan V, Krichevsky AM. MiR-26b, upregulated in Alzheimer’s disease, activates cell cycle entry, tau-phosphorylation, and apoptosis in postmitotic neurons. J Neurosci. 2013;33(37):14645–14659. doi:10.1523/JNEUROSCI.1327-13.2013
   PubMed Web of Science ®Google Scholar
• Müller M, Kuiperij HB, Versleijen AA, et al. Validation of microRNAs in cerebrospinal fluid as biomarkers for different forms of dementia in a multicenter study. J Alzheimers Dis. 2016;52(4):1321–1333. doi:10.3233/JAD-160038
   PubMedGoogle Scholar
• Du P, Wang J, Han Y, Feng J. Blocking the LncRNA MALAT1/miR-224-5p/NLRP3 axis inhibits the hippocampal inflammatory response in T2DM with OSA. Front Cell Neurosci. 2020;14:97. doi:10.3389/fncel.2020.00097
   PubMed Web of Science ®Google Scholar